Economic outcomes for celecoxib: A systematic review of pharmacoeconomic studies

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 12, Issue 4, 2012, Pages 505-523

  Huelin, Rachel ^a   Pokora, Tiffany ^a   Foster, Talia S ^a   Mould, Joaquin F ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

Author keywords

celecoxib; cost effective; COX 2; nonselective NSAID; osteoarthritis; review; rheumatoid arthritis

Indexed keywords

BISMUTH SALICYLATE; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; HYALURONIC ACID; IBUPROFEN; METRONIDAZOLE; MISOPROSTOL; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PARACETAMOL; PIROXICAM; PLACEBO; PROTON PUMP INHIBITOR; ROFECOXIB; TETRACYCLINE;

ASIA; COST BENEFIT ANALYSIS; COST UTILITY ANALYSIS; DRUG COST; DRUG SAFETY; ECONOMIC EVALUATION; FUNCTIONAL STATUS; GASTROINTESTINAL TOXICITY; HEALTH CARE COST; HEALTH CARE SYSTEM; HEALTH ECONOMICS; HUMAN; KNEE OSTEOARTHRITIS; MEXICO; MONOTHERAPY; OSTEOARTHRITIS; PHARMACOECONOMICS; QUALITY OF LIFE; REVIEW; RHEUMATOID ARTHRITIS; SYSTEMATIC REVIEW; TREATMENT RESPONSE; TURKEY (REPUBLIC); UNITED STATES;

ARTHRITIS, RHEUMATOID; COST OF ILLNESS; COST-BENEFIT ANALYSIS; CYCLOOXYGENASE 2 INHIBITORS; ECONOMICS, PHARMACEUTICAL; HEALTH CARE COSTS; HUMANS; MODELS, ECONOMIC; OSTEOARTHRITIS; PYRAZOLES; QUALITY OF LIFE; SULFONAMIDES;

EID: 84866694880     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/erp.12.36     Document Type: Review

References (11)

1. Pugliese JM, Morey AF, Peterson AC. Lichen sclerosus: Review of the literature and current recommendations for management. J Urol 2007;178:2268-76.
2. Meffert JJ, Davis BM, Grimwood RE. Lichen sclerosus. J Am Acad Dermatol 1995;32:393-416.
3. Kulkarni S, Barbagli G, Kirpekar D, Mirri F, Lazzeri M. Lichen sclerosus of the male genitalia and urethra: Surgical options and results in a multicenter international experience with 215 patients. Eur Urol 2009;55:945-54.
4. Gargollo PC, Kozakewich HP, Bauer SB, Borer JG, Peters CA, Retik AB, et al. Balanitis xerotica obliterans in boys. J Urol 2005;174:1409-12.
5. Christman MS, Chen JT, Holmes NM. Obstructive complications of lichen sclerosus. J Pediatr Urol 2009;5:165-9.
6. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 1999; 353:1777-83.
7. Das S, Tunuguntla HS. Balanitis xerotica obliterans-a review. World J Urol 2000;18:382-7.
8. Kiss A, Király L, Kutasy B, Merksz M. High incidence of balanitis xerotica obliterans in boys with phimosis: Prospective 10-year study. Pediatr Dermatol 2005;22:305-8.
9. Meuli M, Briner J, Hanimann B, Sacher P. Lichen sclerosus et atrophicus causing phimosis in boys: A prospective study with 5-year followup after complete circumcision. J Urol 1994;152:987-9.
10. Depasquale I, Park AJ, Bracka A. The treatment of balanitis xerotica obliterans. BJU Int 2000;86:459-65.
11. Powell JJ, Wojnarowska F. Lichen sclerosus. Lancet 1999;22: 1777-83.